Vavricka Stephan R, Greuter Thomas, Scharl Michael, Mantzaris Gerassimos, Shitrit Ariella B, Filip Rafal, Karmiris Konstantinos, Thoeringer Christoph K, Boldys Hubert, Wewer Anne V, Yanai Henit, Flores Cristina, Schmidt Carsten, Kariv Revital, Rogler Gerhard, Rahier Jean-François
Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland Division of Gastroenterology and Hepatology, Triemli Hospital Zurich, Zurich, Switzerland.
Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
J Crohns Colitis. 2015 Oct;9(10):886-90. doi: 10.1093/ecco-jcc/jjv128. Epub 2015 Jul 17.
Cogan's syndrome (CSy) is a very rare autoimmune disorder, mainly affecting the inner ear and the eye, and is associated with inflammatory bowel disease (IBD).
This was a European Crohn's and Colitis Organisation (ECCO) retrospective observational study, performed as part of the CONFER project. A call to all ECCO members was made to report concomitant CSy and inflammatory bowel disease (IBD) cases. Clinical data were recorded in a standardized questionnaire.
This international case series reports on 22 concomitant CSy-IBD cases from 14 large medical centres. Mean duration of IBD until diagnosis of CSy was 8.7 years (range 0.0-38.0) and mean age at CSy diagnosis was 44.6 years (range 9.0-67.0). Six patients had underlying ulcerative colitis (UC) and 16 had Crohn's disease. Eleven patients (50%) had active disease at CSy diagnosis. Sixteen patients were under IBD treatment at the time of CSy diagnosis, of whom 6 (37.5%) were on anti-tumour necrosis factor (TNF). Seven out of 10 patients, who were treated for CSy with immunomodulators (mostly with corticosteroids), demonstrated at least partial response.
This is the largest CSy-IBD case series so far. Although CSy is considered to be an autoimmune disease and is associated with IBD, immunomodulatory IBD maintenance treatment and even anti-TNF therapy do not seem to prevent disease onset. Moreover, IBD disease activity does not seem to trigger CSy. However, vigilance may prompt early diagnosis and directed intervention with corticosteroids at inception may potentially hinder audiovestibular deterioration. Finally, vigilance and awareness may also offer a better setting to study the pathophysiological mechanisms of this rare but debilitating phenomenon.
科根综合征(CSy)是一种非常罕见的自身免疫性疾病,主要影响内耳和眼睛,并与炎症性肠病(IBD)相关。
这是一项欧洲克罗恩病和结肠炎组织(ECCO)的回顾性观察研究,作为CONFER项目的一部分进行。向所有ECCO成员发出呼吁,报告同时患有CSy和炎症性肠病(IBD)的病例。临床数据记录在标准化问卷中。
这个国际病例系列报告了来自14个大型医疗中心的22例CSy-IBD合并病例。IBD诊断为CSy之前的平均病程为8.7年(范围0.0 - 38.0),CSy诊断时的平均年龄为44.6岁(范围9.0 - 67.0)。6例患者患有溃疡性结肠炎(UC),16例患有克罗恩病。11例患者(50%)在CSy诊断时有活动性疾病。16例患者在CSy诊断时正在接受IBD治疗,其中6例(37.5%)正在接受抗肿瘤坏死因子(TNF)治疗。10例接受免疫调节剂(主要是皮质类固醇)治疗CSy的患者中,有7例至少有部分反应。
这是迄今为止最大的CSy-IBD病例系列。尽管CSy被认为是一种自身免疫性疾病且与IBD相关,但免疫调节性IBD维持治疗甚至抗TNF治疗似乎并不能预防疾病的发生。此外,IBD疾病活动似乎也不会引发CSy。然而,保持警惕可能会促使早期诊断,并且在发病初期使用皮质类固醇进行针对性干预可能会潜在地阻碍听觉前庭功能恶化。最后,保持警惕和提高认识也可能为研究这种罕见但使人衰弱的现象的病理生理机制提供更好的条件。